Search
News
Genpact Q2 2026 Earnings: Advanced Technology Solutions Drives Growth
Genpact’s Q2 2026 net revenue rose 7.1% year over year to $1.343 billion, while diluted EPS increased 14.7% to $0.86. Advanced Technology Solutions revenue grew 24.1% to $363 million and supplied most of the company’s incremental revenue, offsetting slower 1.9% growth in Core Business Services. Gross margin reached 36.5%, but quarterly operating cash flow fell to $72 million from $177 million. Genpact raised its full-year Advanced Technology Solutions growth outlook to at least 25% and adjusted diluted EPS growth guidance to at least 12%.
TradingKey
Thu, Aug 6
Amphastar Q2 2026 Earnings: New Products Lift Revenue and Gross Margin
Amphastar Pharmaceuticals’ Q2 2026 revenue rose 5% to $183.9 million, while GAAP diluted EPS increased to $0.67 from $0.64. Gross margin expanded 120 basis points to 50.8% as higher-margin launches offset pricing pressure in BAQSIMI and glucagon. Operating income declined to $39.7 million as selling, administrative, and R&D expenses increased. Six-month operating cash flow was $99.2 million, while a $100 million BAQSIMI milestone payment to Eli Lilly is due in Q3 2026.
TradingKey
Thu, Aug 6
CleanSpark Fiscal Q3 2026 Earnings: Bitcoin Valuation Losses Drive a $239.8 Million Net Loss
CleanSpark’s fiscal Q3 2026 revenue fell 30.5% year over year to $138.0 million, while diluted EPS swung to a loss of $0.89 from income of $0.78. The company recorded a $239.8 million net loss and negative adjusted EBITDA of $113.0 million, with a $116.3 million fair-value loss on bitcoin and weaker mining economics weighing on results. CleanSpark ended June 30 with $202.6 million in cash, $814.9 million in bitcoin holdings and related collateral assets, and $1.8 billion in long-term debt as it advanced the Sandersville data center lease.
TradingKey
Thu, Aug 6
ICF Q2 2026 Earnings: Margins Hold as Federal Revenue Declines
ICF’s Q2 2026 revenue was $474.5 million, down about 0.4% year over year, while GAAP diluted EPS increased 16.4% to $1.49. Adjusted EBITDA was $53.4 million with an 11.2% margin, as growth in commercial and international government work offset a 9.5% decline in federal revenue. A lower 17.8% tax rate also supported earnings growth. ICF reaffirmed its 2026 revenue and EPS guidance, while a $9.3 billion pipeline and 1.09 trailing book-to-bill ratio contrasted with delayed federal procurement decisions during the quarter.
TradingKey
Thu, Aug 6
Cryoport Q2 2026 earnings: Services growth brings adjusted EBITDA above zero
Cryoport’s Q2 2026 revenue rose 8% year over year to $49.0 million, led by 15% growth in Life Sciences Services, while Life Sciences Products revenue was essentially flat at $21.0 million. Adjusted EBITDA from continuing operations improved to positive $0.4 million from negative $0.9 million, but the company still recorded a $0.20 diluted loss per share. Overall gross margin edged down to 46.6%, as better services margins were offset by weaker products margins. Cryoport ended the quarter with $396.7 million in cash, cash equivalents and short-term investments.
TradingKey
Thu, Aug 6
The RealReal Q2 2026 Earnings: GMV Growth Expands Adjusted EBITDA Margin
The RealReal’s Q2 2026 revenue rose 17% to $192.6 million as GMV increased 22% to a record $617.3 million. Adjusted EBITDA nearly doubled to $13.5 million, lifting the margin to 7.0% from 4.1%, while gross margin reached 74.4%. GAAP net loss widened to $27.2 million because of an $18.6 million non-cash warrant-liability remeasurement. Q2 free cash flow remained negative at $6.1 million, though it improved from a $15.0 million outflow. The company also raised its full-year GMV and adjusted EBITDA guidance.
TradingKey
Thu, Aug 6
Citizens Q2 2026 Earnings: Premium Growth Could Not Offset Reserve Pressure
Citizens, Inc. reported Q2 2026 revenue of $60.4 million, down from $65.1 million a year earlier, as investment-related results weakened despite higher insurance premiums. Diluted EPS swung to a $0.01 loss from $0.13 of income, while adjusted net income fell to $0.8 million from $4.2 million. Direct insurance premiums rose to $48.1 million, but higher future policy benefit reserves—primarily tied to Domestic Insurance growth and a tougher comparison with prior-year reserve releases—more than offset lower claims and surrenders. Operating cash flow remained positive at $1.7 million.TradingKey
Thu, Aug 6
IBC Q2 2026 Earnings: Net Income and EPS Fall 4.3%
IBC’s Q2 2026 earnings showed net income of $95.8 million and diluted EPS of $1.54, both down 4.3% from a year earlier. For the first six months, net income edged up 0.5% to $198.0 million as interest earned on larger loan and investment portfolios and lower deposit interest expense supported results. Net loans reached about $9.7 billion at June 30, up from $9.3 billion at year-end, while higher credit-loss provisions linked to loan growth and non-accrual balances offset part of the benefit.
TradingKey
Thu, Aug 6
WFCF Q2 2026 Earnings: Margin Expansion Lifted Operating Income
Where Food Comes From (WFCF) reported Q2 2026 revenue of $6.611 million, up 1% year over year, while diluted EPS fell to $0.08 from $0.11. Gross margin expanded to 40.6% from 37.5%, helping operating income rise 21% to $665,000. However, a $240,000 unfavorable swing in the fair value of digital assets reduced net income to $413,000. Verification revenue edged higher, product sales declined, and management said RaiseWell enrollment and non-beef certification programs helped offset pressure from high beef prices and smaller herd sizes.
TradingKey
Thu, Aug 6
Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive
Sonoma Pharmaceuticals reported fiscal Q1 2027 revenue of $6.4 million, up 60% year over year, while U.S. revenue increased 141%. Gross profit reached $2.6 million and gross margin expanded to 40% from 36%. With operating expenses unchanged at $2.6 million, the net loss narrowed to $0.3 million from $1.2 million, and company-reported EBITDA improved to a $0.1 million gain. The quarter also included an FDA 510(k) clearance for Microdacyn and new distributors in Taiwan, Vietnam, and the United States.
TradingKey
Thu, Aug 6
Loar Q2 2026 Earnings: Revenue Rises 39% as Adjusted EBITDA Margin Expands
Loar Holdings’ Q2 2026 earnings showed net sales of $171.6 million, up 39.4% year over year, while organic sales rose 12.3%. Adjusted EBITDA increased 47.4% to $69.4 million and its margin expanded to 40.5% from 38.3%. GAAP net income remained flat at $16.7 million as higher interest expense and acquired-intangible amortization offset operating gains, highlighting the gap between acquisition-supported growth, adjusted profitability, and bottom-line earnings.
TradingKey
Thu, Aug 6
MarketWise Q2 2026 Earnings: Billings Rise 57% as GAAP Revenue Falls
MarketWise reported Q2 2026 total net revenue of $75.8 million, down 5.2% year over year, and a diluted loss of $0.24 per share versus earnings of $0.53 a year earlier. Billings rose 56.7% to $91.2 million, while operating cash flow increased 25.7% to $22.4 million. Higher customer acquisition and retention supported current sales, but deferred revenue timing and increased marketing spending produced a $2.6 million net loss. The company raised full-year billings guidance by 10% to approximately $330 million.
TradingKey
Thu, Aug 6
Liberty Capital Q2 2026 Earnings: Flat Revenue, Lower Operating Margins
Liberty Capital reported Q2 2026 revenue of $261 million, flat year over year, while operating income fell 43% to $29 million and Adjusted OIBDA declined 11% to $96 million. Consumer margins benefited from lower video programming costs after the 2025 exit, but higher business distribution and circuit costs drove a sharp decline in consolidated profitability. The company also entered the second half with heavier capital spending, higher leverage tied partly to Quintillion financing, and plans to begin a recurring quarterly dividend in December 2026, subject to board declaration.
TradingKey
Thu, Aug 6
Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028
Praxis Precision Medicines’ Q2 2026 results showed a net loss of $83.7 million, up from $71.1 million a year earlier, while diluted loss per share narrowed to $2.87 from $3.31 because the weighted-average share count increased. R&D expense rose to $69.4 million and G&A expense more than doubled to $27.5 million. Cash, cash equivalents and marketable securities totaled approximately $1.4 billion at June 30, supporting operations into 2028 as Praxis prepares for regulatory decisions on relutrigine and ulixacaltamide and advances key epilepsy studies.
TradingKey
Thu, Aug 6
CRA Fiscal Q2 2026 Earnings: Revenue Rises 12.8% as Guidance Increases
Charles River Associates (CRA) reported fiscal Q2 2026 revenue of $210.8 million, up 12.8% year over year, while diluted EPS increased 17.3% to $2.10. Non-GAAP EBITDA rose 15.3% to $26.8 million, with margin improving to 12.7%, supported by broad practice, service-line and geographic growth. CRA raised its constant-currency full-year revenue guidance to $805 million-$820 million and maintained a 12.0%-13.0% non-GAAP EBITDA margin outlook. Investors should also monitor higher service costs, negative first-half operating cash flow and increased borrowing.
TradingKey
Thu, Aug 6
Acorn Energy Q2 2026 Earnings: Recurring Revenue Mix Lifts Gross Margin
Acorn Energy’s Q2 2026 revenue fell 29.4% year over year to $2.489 million, and diluted EPS declined to $0.12 from $0.28 as hardware sales dropped 51.7%. Recurring monitoring revenue rose 8.0% to $1.425 million, shifting the mix toward higher-margin services and lifting gross margin by 750 basis points to 82.4%. The quarter highlights both the resilience of monitoring revenue and the earnings sensitivity to large hardware deployments, while the Champion partnership and OMNI360 launch provide future growth avenues without quantified near-term revenue visibility.TradingKey
Thu, Aug 6
MBX Biosciences Q2 2026 Earnings: Clinical Spending Widens Net Loss
MBX Biosciences’ Q2 2026 results showed a net loss of $37.1 million, or $0.78 per diluted share, as R&D expense rose to $31.0 million from $17.7 million. Cash, cash equivalents and marketable securities totaled $418.6 million at June 30 and are expected to fund the current operating plan into 2029. Operational progress centered on canvuparatide’s move toward Phase 3 and preliminary MBX 4291 obesity data, with the next 12-week multiple-ascending-dose readout scheduled for Q4 2026.
TradingKey
Thu, Aug 6
Aligos Q2 2026 earnings: Licensing revenue narrows the quarterly loss
Aligos Therapeutics (ALGS) reported Q2 2026 revenue of $27.8 million, compared with $1.0 million a year earlier, as licensing revenue offset a roughly 72% increase in R&D spending. Net loss narrowed to $1.5 million, or $0.14 per diluted share, from $15.9 million, or $1.53 per share. Cash, equivalents and investments were $30.4 million at June 30, excluding a $25 million upfront payment received in July. The company’s funding runway extends through Q4 2026, while B-SUPREME topline data are expected in late Q3 2027.
TradingKey
Thu, Aug 6
Prime Medicine Q2 2026 Earnings: Lower Costs Narrow the Net Loss
Prime Medicine’s Q2 2026 earnings showed collaboration revenue of $1.154 million, up about 3.5% year over year, while net loss narrowed to $42.1 million and EPS improved to -$0.24 from -$0.41. R&D and G&A spending declined after workforce, facility, compensation, and legal-cost reductions. The company ended June with $108.8 million in cash, investments, and restricted cash, which it expects to fund operations into 2027 as PM577a enters Phase 1/2 startup, PM647 approaches a regulatory filing, and PM359 advances toward a planned BLA submission.
TradingKey
Thu, Aug 6
ALX Oncology Q2 2026 Results: Lower R&D Spending Narrows Net Loss
ALX Oncology’s Q2 2026 results showed a GAAP net loss of $18.0 million, or $0.13 per share, compared with $25.9 million, or $0.49 per share, a year earlier. R&D expense fell to $13.1 million as legacy-trial costs declined, while cash, cash equivalents and investments reached $153.4 million at June 30. The company says this liquidity can fund planned operations through the first half of 2028. Investors are now focused on ALX2004 safety data in the second half of 2026 and the ASPEN-09-Breast topline readout expected in mid-2027.
TradingKey
Thu, Aug 6
Featured Tools
Top News
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
The Week Ahead: Fed Minutes, Walmart, Target and Home Depot Earnings to Test US Consumer Resilience
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
SK Hynix Stock Forecast: Can HBM4 Demand Drive a Breakout Toward $194?
Broadcom Stock Price Forecast: Can It Break $500 Before Earnings Amid Strong Custom AI Chip Demand?
